Audentes Announces Positive Interim Data from First Dose Cohort of ASPIRO, a Phase 1/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy

Audentes Therapeutics, Inc.SAN FRANCISCO, Jan. 4, 2018 /PRNewswire/ -- Conference call and webcast January 4, 2018 at 8:00am ESTWebcast may be accessed via the Investor and Media page of the Audentes websiteCall may be accessed by dialing 1-833-659-8620 and using conference ID#: 4957669 Audentes...